Free Trial

Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem

Generic drugs and pill bottles

Key Points

  • Teva Pharmaceuticals is the world’s largest generic drug manufacturer with over 500 drugs and is experiencing robust growth in all geographies.
  • Growth in Q1 2024 was led by its generics business and leading branded drug, AUSTEDO, which had 61% YoY revenue growth.
  • Teva shares trade at just 7.25x forward earnings and will launch a generic version of Stelara in February 2025.
  • 5 stocks we like better than Teva Pharmaceutical Industries

Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024, the average price hike was 5.4% on over 700 brand drugs. Their generic versions are alternatives to brand drugs, which come at a significant discount. This is why insurers, payers, and federal health insurance plans prefer generics and biosimilar drugs.

Teva Pharmaceutical Industries Today

Teva Pharmaceutical Industries Limited stock logo
TEVATEVA 90-day performance
Teva Pharmaceutical Industries
+0.18 (+1.05%)
(As of 07/12/2024 08:52 PM ET)
52-Week Range
Price Target

Teva Pharmaceuticals Industries Ltd. NYSE: TEVA is a leader in the generic drug industry. While it sells over 500 generic drugs at a discount (to the brands), its stock is also selling at a discount. It trades at just 7.25x forward earnings. Value investors may want to scoop up shares while they are still cheap. 

Teva Pharmaceutical operates in the medical sector, competing with Sandoz Group AG OTCMKTS: SDZNY, AbbVie Inc. NYSE: ABBV, Merck & Co. Inc. NYSE: MRK and  Dr. Reddy’s Laboratories Ltd. NYSE: RDY.

Teva’s Has the Largest Portfolio of Generic Medicines

Teva is the world's largest generic drug company. Its portfolio extends to over 500 generic drugs, most as essential. The company is diligent with its first-to-file and first-to-market strategy. It has built a vast distribution network, expanding its global reach to numerous countries worldwide, reaching 200 million people who use their drugs every day. They also have the capacity for high-volume production of generic and brand drugs. In late May 2024, Teva and Alvotech NASDAQ: ALVO launched Simlandi, a generic version of Humira. Humira is the blockbuster arthritis medication produced by AbbVie. 

The company has announced its intent to sell its active pharmaceutical ingredients (API) business called TAPI as part of its Pivot to Growth initiative, which has the company refocused on its core business. No actual buyers or prices have been mentioned, but it's estimated that the business could be worth up to $2 billion.

Teva Also Develops Its Own Branded Drugs

While best known for its library of generics, Teva also develops and produces its own brand drugs. AUSTEDO is one of its primary branded drugs. It is used to treat chorea associated with Huntington’s disease. AJOVY is an adult migraine medication.

Teva Pharmaceuticals stock chart

TEVA Stock is in a Descending Triangle Pattern

The daily candlestick chart on TEVA illustrates a descending triangle pattern. The descending trendline formed at the $17.69 swing high on June 12, 2024, acting as an upper trendline resistance down to the flat-bottom lower trendline support at $16.16. The daily relative strength index (RSI) has turned back down and fallen to the 47-band. Pullback support levels are at $16.16, $15.62, $15.00, and $14.54.

Teva’s Revenue Growth Driven by Generics and AUSTEDO in Q1 2024

Teva Pharmaceutical Industries MarketRank™ Stock Analysis
Overall MarketRank™
2.40 out of 5
Analyst Rating
Moderate Buy
7.4% Upside
Short Interest
Dividend Strength
News Sentiment
1.00mentions of Teva Pharmaceutical Industries in the last 14 days
Insider Trading
Selling Shares
Projected Earnings Growth
See Full Details

On May 8, 2024, Teva Pharmaceuticals reported Q1 2024 EPS of 48 cents, missing consensus estimates by 3 cents. Revenues rose 4.3% YoY to $3.82 billion, beating consensus estimates for $3.73 billion. Growth was led by its generics business and AUSTEDO. Generics saw growth across all regions, rising 9% in local currency terms. AUSTEDO experienced 67% YoY growth in the U.S. as the company reaffirmed 2024 revenue forecasts of $1.5 billion. AJOVY revenues rose 18% YoY to $113 million. The company received FDA approvals for generics SIMLANDI and SELARSDI, which are generic versions of Humira and Stelara, respectively.

For the full year of 2024, Teva Pharmaceuticals reaffirmed its revenue forecast of $15.7 billion to $16.3 billion. Adjusted EBITDA is expected to be between $4.5 billion and $5 billion. Non-GAAP diluted EPS is expected to be between $2.20 and 2.50. Free cash flow is expected to be between $1.7 billion and $2 billion.

Upbeat CEO Comments on 1st Anniversary of Teva's Pivot to Growth Strategy

TEVA CEO Richard Francis stated that the company is off to a great start, driven by growth in its generics business across all geographies and robust sales of its branded drugs AUSTEDO and AJOVY. The company has made significant strides in its Pivot to Growth Strategy. Phase 3 efficacy results for olanzapine once-monthly LAI met its primary endpoint, indicating it to be a well-tolerated treatment option for schizophrenia. The Pivot to Growth Strategy focuses on accelerating growth engines, which are AUSTEDO, AJOVY, and UZEDY branded drugs and late-stage pipeline generics.

CEO Francis commented, “We're excited to be in a position in quarter two to be launching our biosimilar Humira and SIMLANDI, and we're getting good interest from the payers, the PBMs and the channel with regard to this. Also pleased with the fact that our biosimilar Stelara is also approved, and we'll be launching that in February of 2025.” 

Teva Pharmaceuticals analyst ratings and price targets are at MarketBeat. 

Should you invest $1,000 in Teva Pharmaceutical Industries right now?

Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report
Jea Yu
About The Author

Jea Yu

Contributing Author

Trading Strategies

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Teva Pharmaceutical Industries (TEVA)
2.4054 of 5 stars
2.41 / 5 stars
$17.28+1.1%N/A-42.15Moderate Buy$18.56
AbbVie (ABBV)
4.4986 of 5 stars
4.50 / 5 stars
$170.28+0.2%3.64%50.53Moderate Buy$182.69
Merck & Co., Inc. (MRK)
4.2727 of 5 stars
4.27 / 5 stars
$127.76-0.9%2.41%141.96Moderate Buy$135.36
Dr. Reddy's Laboratories (RDY)
0.4593 of 5 stars
0.46 / 5 stars
Alvotech (ALVO)
1.4871 of 5 stars
1.49 / 5 stars
$12.15+2.0%N/A-5.84Moderate Buy$16.00
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines